Novalis LifeSciences Closes First Investment Fund, at $85M

NovalisNovalis LifeSciences, a Hampton, N.H.-based investment and advisory firm for the Life Science industry, raised $85M in capital for its first fund.

Novalis LifeSciences Investments I, L.P., is a growth-oriented fund that will invest in 8-12 companies that are commercializing breakthrough technologies in various segments of the Life Science industry. This includes:
– drug discovery,
– life science tools,
– genomics,
– synthetic biology,
– diagnostics, and
– agricultural biotechnology.

Founded and managed by Dr. Marijn E. Dekkers, current chairman of Unilever and former chief executive officer of Bayer AG and Thermo Fisher Scientific Inc., Novalis LifeSciences is a globally acting venture capital firm focused on breakthrough technologies in Life Science working with a diversified group of project-based specialists leading in their respective fields.



Join the discussion